AngioChem
AngioChem is a Montreal-based, clinical-stage biotechnology company developing engineered peptide-drug and peptide-antibody conjugates that cross the blood-brain barrier via the LRP-1 pathway (EPiC platform), targeting CNS diseases including brain cancer, brain metastases, pain, and lysosomal storage disorders.
- Company typePrivate
- Founded2003
- HeadquartersMontréal, Canada
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What AngioChem does
AngioChem is a privately held, clinical-stage biotechnology company founded in 2003 and headquartered in Montreal, Canada. The company is developing a class of engineered peptide-drug and peptide-antibody conjugates built on its proprietary EPiC (Engineered Peptide Compounds) platform technology, which uses the Angiopep-2 peptide vector to deliver therapeutic payloads across the blood-brain barrier via receptor-mediated transcytosis through the LRP-1 pathway — addressing the fundamental challenge that >95% of drugs cannot reach the brain.
The lead asset, ANG1005, is a paclitaxel-Angiopep-2 conjugate that has received FDA Orphan Drug and Fast Track designations for glioblastoma multiforme and was advancing into Phase III clinical trials for leptomeningeal carcinomatosis and brain metastases from HER2-negative breast cancer as of 2019, supported by a $4 million Quebec government loan. The pipeline additionally includes ANG4043 (brain-penetrant anti-HER2 antibody conjugate), ANG2002 (neuropeptide conjugate for pain), ANG1007 and ANG1009 (doxorubicin and etoposide conjugates), and enzyme conjugates such as ANG-EPiC IDUA for lysosomal storage diseases. Clinical efficacy signals include 71% disease control in brain metastases patients and 20-25x higher tumor paclitaxel concentrations versus free drug in patient samples.
AngioChem operates as a partner-dependent drug developer with no commercialized products and no disclosed product revenue. The company's monetization model targets out-licensing and royalties, demonstrated through collaborations with GlaxoSmithKline (LSDs, 2012), Geron (oncology, 2010), and Xinogen (China rights, 2018). Total disclosed equity and debt funding since inception approximates $21 million, with $7.5 million raised in a 2018 Series C and a 2019 government loan backing Phase III work. The company employs 11-50 staff, runs conference-driven scientific engagement (AACR, ASCO, ESMO, San Antonio Breast Cancer Symposium, Society for Neuroscience), and is led by CEO Dr. Jean-Paul Castaigne (MD, MBA) and Executive Chairman John Huss, with Scientific Founder Dr. Richard Béliveau serving as advisor.
AngioChem firmographics
Firmographics- Name
- AngioChem
- Legal name
- Angiochem Inc.
- Website
- https://angiochem.com
- Company type
- Private
- Founded year
- 2003
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- AngioChem is a Montreal-based, clinical-stage biotechnology company developing engineered peptide-drug and peptide-antibody conjugates that cross the blood-brain barrier via the LRP-1 pathway (EPiC platform), targeting CNS diseases including brain cancer, brain metastases, pain, and lysosomal storage disorders.
- Ownership category
- akta.pro rank
AngioChem industry classification
Industry- Product category
- Biopharmaceutical Drug Development (CNS/Blood-Brain Barrier Delivery)
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
- akta.pro secondary industry
- Specialty Care Pharmaceuticals (HLAIAAAB)
Keywords
Where AngioChem is headquartered
LocationHeadquarters
- HQ city
- Montréal
- HQ country
- Canada
- HQ region
- North America
Offices1 record
Markets served
AngioChem business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Clinical-stage Drug Development: Pre-revenue clinical-stage biotechnology company developing novel therapeutics. Revenue generation expected through pharmaceutical partnerships, licensing agreements, and eventual product commercialization. Currently focused on advancing ANG1005 through Phase III clinical trials for brain metastases and leptomeningeal carcinomatosis.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels4 records
AngioChem product offering
Product offeringCore offering
AngioChem is a clinical-stage biotechnology company that develops proprietary peptide-drug and peptide-antibody conjugates capable of crossing the blood-brain barrier to treat CNS disorders. Its lead product ANG1005 is an Angiopep-2-paclitaxel conjugate in Phase III development for breast cancer brain metastases and leptomeningeal carcinomatosis, supported by a broader pipeline spanning oncology, pain, and lysosomal storage diseases. Revenue is generated through pharmaceutical licensing and partnership arrangements.
Product overview
AngioChem is a clinical-stage biotechnology company that has developed a proprietary EPiC (Engineered Peptide Compounds) platform technology centered on Angiopep-2, enabling drugs to cross the blood-brain barrier via the LRP-1 pathway. The product portfolio includes ANG1005 (paclitaxel-peptide conjugate for brain cancer and metastases), ANG4043 (brain-penetrant HER2 antibody conjugate), ANG2002 (neuropeptide conjugate for pain), ANG1007/ANG1009 (doxorubicin/etoposide conjugates), and enzyme conjugates for lysosomal storage diseases. These products range from preclinical to Phase III clinical development stages, targeting CNS diseases including glioblastoma, brain metastases, pain, and lysosomal storage disorders.
Differentiator
Problem solved
Functional benefit
Products and services
- ANG1005 ANG1005 is a novel paclitaxel-peptide drug conjugate (Angiopep-2-paclitaxel) that leverages the LRP-1 pathway to cross the blood-brain barrier for treatment of brain cancers including glioblastoma multiforme and brain metastases from breast cancer; it has received FDA Orphan Drug and Fast Track designations and entered Phase III for leptomeningeal carcinomatosis from HER2-negative breast cancer.
- ANG4043 ANG4043 is a brain-penetrant peptide-antibody conjugate of an anti-HER2 monoclonal antibody designed to treat HER2+ breast cancer metastases in the brain, created by conjugating Angiopep-2 to a trastuzumab-like monoclonal antibody.
- ANG2002 ANG2002 is a peptide-drug conjugate using Angiopep-2 linked to neurotensin, developed as a potential first-in-class analgesic drug for cancer pain, post-operative surgery pain, and neuropathic pain without the side effects of opiates.
- ANG1007 ANG1007 is an Angiopep-2-conjugated doxorubicin chemotherapeutic designed for increased brain penetration and potential treatment of brain tumors.
- ANG1009 ANG1009 is an Angiopep-2-conjugated etoposide chemotherapeutic designed for increased brain penetration and potential treatment of brain tumors.
- ANG-EPiC IDUA ANG-EPiC IDUA is Angiopep-2 conjugated to the iduronidase (IDUA) enzyme, designed to cross the blood-brain barrier to address both systemic and CNS symptoms of Hurler disease (MPS I) and other lysosomal storage diseases.
- EPiC Platform The EPiC (Engineered Peptide Compounds) platform enables drugs to cross the blood-brain barrier via receptor-mediated transcytosis using the LRP-1 pathway, creating patentable New Chemical Entities including small molecules, peptides, monoclonal antibodies, and siRNA.
Quantifiable outcome
- 71% disease control rate (15/21 patients) at therapeutic doses with ANG1005 in brain metastases trial
- +3 more outcomes
Companies that use AngioChem
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles2 records
AngioChem technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
AngioChem partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- XinogencoreLicense agreement for AngioChem technology. Xinogen received rights to develop and commercialize AngioChem's products in China.
- GlaxoSmithKline (GSK)coreCollaboration to discover and develop treatments of lysosomal storage diseases. AngioChem provides its EPiC technology platform to enable enzyme therapies to cross the blood-brain barrier for LSDs with CNS involvement.
Scale indicators5 records
Recent moves6 records
Expansion highlights5 records
AngioChem competitors and assessment
Company assessmentDirect peers
- Sage Therapeutics: Clinical-stage CNS-focused company developing therapeutics for neurological conditions. Comparable in clinical-stage CNS specialization and target patient populations, though with different mechanistic approaches.
- Denali Therapeutics: Clinical-stage biotech developing engineered therapeutics to cross the blood-brain barrier using transferrin receptor (TfR)-based delivery technology. Most direct competitor in BBB-enabled CNS therapeutics with significantly larger capital base.
- BioMarin Pharmaceutical: Specialty biopharmaceutical company developing enzyme replacement and CNS-penetrant therapies for rare diseases including lysosomal storage disorders (MPS I, MPS II, MPS VI), directly comparable to AngioChem's ANG-EPiC IDUA program and broader LSD pipeline.
- Geron Corporation: Prior licensee of ANG1005 (as GRN1005) that conducted Phase 2 trials in brain metastases. Geron represents a previous direct partner and oncology-stage peer with overlapping clinical experience in CNS metastases.
- Puma Biotechnology: Specialty oncology company developing HER2-targeted therapies (neratinib) for breast cancer, including in patients with CNS metastases. Directly comparable to AngioChem's ANG4043 brain-penetrant anti-HER2 program.
- ArmaGen Technologies: BBB delivery biotech using an alternative receptor-mediated transcytosis approach (anti-insulin receptor antibody). Direct peer in BBB-shuttle technology though with a different targeting vector than AngioChem's LRP-1/Angiopep-2.
Broad incumbents
- Seagen: Established antibody-drug conjugate (ADC) developer with deep oncology expertise and commercial-stage products. Comparable to AngioChem's brain-penetrant ADC approach and relevant given overlapping payload/cytotoxic agent strategies.
- Daiichi Sankyo: Major global pharmaceutical company with industry-leading ADC platform (Enhertu) including HER2-targeted ADCs. Competitor in brain-penetrant ADC space; comparable to ANG4043 and broader AngioChem ADC constructs.
- Genentech (Roche): Leading oncology company with HER2 franchise (Herceptin, Kadcyla) and active CNS metastases programs. Highly relevant competitor in HER2-positive breast cancer with brain metastases — the same indication space AngioChem is targeting.
- AbbVie: Large pharmaceutical company with significant oncology and neuroscience pipelines including brain-penetrant programs. Potential acquirer/partner for BBB-delivery platform technology; relevant as benchmark for CNS pharma economics.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
AngioChem social profiles
Digital presenceAngioChem compliance and trust
Trust signalCompliance2 records
AngioChem financial estimates
Financial estimateRevenue estimate
Valuation estimate
AngioChem leadership team
Management profileNumber of profiles
Profiles4 records
AngioChem funding detail
Funding detailFunding overview
Funding rounds5 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
AngioChem M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about AngioChem
What does AngioChem do?
AngioChem is a clinical-stage biotechnology company that develops proprietary peptide-drug and peptide-antibody conjugates capable of crossing the blood-brain barrier to treat CNS disorders. Its lead product ANG1005 is an Angiopep-2-paclitaxel conjugate in Phase III development for breast cancer brain metastases and leptomeningeal carcinomatosis, supported by a broader pipeline spanning oncology, pain, and lysosomal storage diseases. Revenue is generated through pharmaceutical licensing and partnership arrangements.
Is AngioChem a public or private company?
AngioChem is a private company. It is classified as venture growth investor backed and is currently operating.
When was AngioChem founded?
AngioChem was founded in 2003. It employs 11 to 50 people.
Where is AngioChem based?
AngioChem is headquartered in Montréal, Canada, in the North America region.
How does AngioChem make money?
One revenue line is on record: clinical-stage Drug Development.
Who are AngioChem's main competitors?
Direct peers on record are Sage Therapeutics, Denali Therapeutics, BioMarin Pharmaceutical, Geron Corporation, Puma Biotechnology and ArmaGen Technologies. Broad incumbents are Seagen, Daiichi Sankyo, Genentech (Roche) and AbbVie.
Does AngioChem have an API?
No public API is recorded for AngioChem.
What industry is AngioChem in?
AngioChem's product category is Biopharmaceutical Drug Development (CNS/Blood-Brain Barrier Delivery). Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAIAAAB, Specialty Care Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2834.